SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volum… Read more
SD Biosensor Inc (137310) - Net Assets
Latest net assets as of September 2025: ₩3.07 Trillion KRW
Based on the latest financial reports, SD Biosensor Inc (137310) has net assets worth ₩3.07 Trillion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩3.98 Trillion) and total liabilities (₩914.08 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩3.07 Trillion |
| % of Total Assets | 77.05% |
| Annual Growth Rate | 84.25% |
| 5-Year Change | 287.07% |
| 10-Year Change | N/A |
| Growth Volatility | 172.47 |
SD Biosensor Inc - Net Assets Trend (2019–2024)
This chart illustrates how SD Biosensor Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SD Biosensor Inc (2019–2024)
The table below shows the annual net assets of SD Biosensor Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩2.93 Trillion | +3.56% |
| 2023-12-31 | ₩2.83 Trillion | -3.91% |
| 2022-12-31 | ₩2.95 Trillion | +33.74% |
| 2021-12-31 | ₩2.20 Trillion | +190.86% |
| 2020-12-31 | ₩757.55 Billion | +449.29% |
| 2019-12-31 | ₩137.91 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to SD Biosensor Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 18785.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩1.79 Trillion | 61.13% |
| Other Components | ₩1.14 Trillion | 38.87% |
| Total Equity | ₩2.92 Trillion | 100.00% |
SD Biosensor Inc Competitors by Market Cap
The table below lists competitors of SD Biosensor Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Equasens S. A.
PA:EQS
|
$174.86 Million |
|
Beijing Kingfore HV & Energy Conservation Technology Co.Ltd.
SHE:001210
|
$174.91 Million |
|
TYC Brother Industrial Co Ltd
TW:1522
|
$174.92 Million |
|
AerSale Corp
NASDAQ:ASLE
|
$174.95 Million |
|
Keystone Technology Co Ltd
SHG:605588
|
$174.73 Million |
|
Holsin Engineering Consulting
SHG:603909
|
$174.71 Million |
|
Hwacom Systems
TWO:6163
|
$174.66 Million |
|
UTI Inc
KQ:179900
|
$174.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SD Biosensor Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,823,659,752,520 to 2,923,334,168,420, a change of 99,674,415,900 (3.5%).
- Net loss of 98,410,897,570 reduced equity.
- Dividend payments of 38,065,910 reduced retained earnings.
- Share repurchases of 18,425,385,760 reduced equity.
- Other factors increased equity by 216,548,765,140.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-98.41 Billion | -3.37% |
| Dividends Paid | ₩38.07 Million | -0.0% |
| Share Repurchases | ₩18.43 Billion | -0.63% |
| Other Changes | ₩216.55 Billion | +7.41% |
| Total Change | ₩- | 3.53% |
Book Value vs Market Value Analysis
This analysis compares SD Biosensor Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.33x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.53x to 0.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ₩1429.57 | ₩7900.00 | x |
| 2020-12-31 | ₩8015.86 | ₩7900.00 | x |
| 2021-12-31 | ₩21316.76 | ₩7900.00 | x |
| 2022-12-31 | ₩28794.15 | ₩7900.00 | x |
| 2023-12-31 | ₩23079.02 | ₩7900.00 | x |
| 2024-12-31 | ₩23893.70 | ₩7900.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SD Biosensor Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.17%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.33x
- Recent ROE (-3.37%) is below the historical average (24.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 2.36% | 4.32% | 0.43x | 1.27x | ₩-10.19 Billion |
| 2020 | 82.30% | 36.51% | 1.15x | 1.95x | ₩540.83 Billion |
| 2021 | 48.61% | 36.34% | 0.97x | 1.37x | ₩845.72 Billion |
| 2022 | 30.95% | 31.08% | 0.90x | 1.11x | ₩616.93 Billion |
| 2023 | -16.56% | -71.33% | 0.17x | 1.34x | ₩-750.08 Billion |
| 2024 | -3.37% | -14.17% | 0.18x | 1.33x | ₩-390.74 Billion |
Industry Comparison
This section compares SD Biosensor Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $74,584,934,889
- Average return on equity (ROE) among peers: -101.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SD Biosensor Inc (137310) | ₩3.07 Trillion | 2.36% | 0.30x | $174.83 Million |
| DIO Corporation (039840) | $194.43 Billion | 1.70% | 0.89x | $94.83 Million |
| Cellumed Co. Ltd (049180) | $5.18 Billion | -719.12% | 11.54x | $32.46 Million |
| Dentium (145720) | $291.10 Billion | 19.06% | 0.96x | $192.13 Million |
| M.I.TECH Co.Ltd (179290) | $14.71 Billion | 4.08% | 0.17x | $45.98 Million |
| JETEMA Co. Ltd (216080) | $-5.04 Billion | 0.00% | 0.00x | $148.99 Million |
| Biodyne Co. Ltd. (314930) | $6.58 Billion | -30.82% | 2.54x | $144.24 Million |
| HASS Corp (450330) | $15.15 Billion | 11.85% | 0.93x | $11.51 Million |